First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743

MLA

Arnaud Scherpereel, et al. First-Line Nivolumab plus Ipilimumab versus Chemotherapy for the Treatment of Unresectable Malignant Pleural Mesothelioma: Patient-Reported Outcomes in CheckMate 743. Mar. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0e6db15a71fb123abecc807eb485cd80&authtype=sso&custid=ns315887.

APA

Arnaud Scherpereel, Scott Antonia, Yolanda Bautista, Francesco Grossi, Dariusz Kowalski, Gérard Zalcman, Anna K. Nowak, Nobukazu Fujimoto, Solange Peters, Anne S. Tsao, Aaron S. Mansfield, Sanjay Popat, Xiaowu Sun, Rachael Lawrance, Xiaoqing Zhang, Melinda J. Daumont, Bryan Bennett, Mike McKenna, & Paul Baas. (2022). First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.

Chicago

Arnaud Scherpereel, Scott Antonia, Yolanda Bautista, Francesco Grossi, Dariusz Kowalski, Gérard Zalcman, Anna K. Nowak, et al. 2022. “First-Line Nivolumab plus Ipilimumab versus Chemotherapy for the Treatment of Unresectable Malignant Pleural Mesothelioma: Patient-Reported Outcomes in CheckMate 743,” March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0e6db15a71fb123abecc807eb485cd80&authtype=sso&custid=ns315887.